08 / 74 · 1:02 · Original AXON film
Argireline (acetyl hexapeptide-8)
The burned-in captions and transcript carry the scientific claims and their limitations. The visuals are conceptual illustrations, not validated molecular models or experimental images. The video has no voice or audio. The full explanation is visible on screen; optional accessible captions are available in the player.
Read every result in its study context. A cell experiment, animal model, exploratory analysis and controlled human trial answer different questions.
Prepared 05 November 2026. Regulatory status is jurisdiction- and date-specific. No claim of specialist review or exhaustive evidence coverage.
Transcript
ARGIRELINE | Acetyl hexapeptide-8
Argireline is the cosmetic name for acetyl hexapeptide-eight. Its evidence is worth separating from the popular Botox comparison. [1] [2]
HUMAN TRIAL | 60 people, 4 weeks
A small placebo-controlled study in sixty people reported improvement in eye-area wrinkles after four weeks. That is human evidence, but it is short-term and formulation-specific. [1]
Delivery is part of the question
The proposed signalling mechanism comes from laboratory work. Whether a topical peptide reaches the relevant tissue in meaningful amounts depends on skin penetration and formulation. [2]
Cosmetic outcome, bounded evidence
These studies do not make a cream equivalent to injected botulinum toxin. Describe the measured cosmetic outcome, and keep the size, duration and limitations of the trial visible. [1] [2] [3]
Sources and context
These linked sources support the evidence distinctions in this short overview. This is not a systematic review, endorsement or treatment recommendation.
- The anti-wrinkle efficacy of argireline, a synthetic hexapeptide, in Chinese subjects: a randomized, placebo-controlled study →Primary human topical trial; 60 subjects, four weeks
- Acetyl Hexapeptide-8 in Cosmeceuticals: A Review of Skin Permeability and Efficacy →Peer-reviewed synthesis; delivery and clinical limitations
- FDA: Cosmetics and U.S. Law →US regulator; cosmetic versus drug framework
